Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2025)

Arcus Biosciences has reported Total Current Liabilities over the past 9 years, most recently at $231.0 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $231.0 million for Q4 2025, up 2.21% from a year ago — trailing twelve months through Dec 2025 was $231.0 million (up 2.21% YoY), and the annual figure for FY2025 was $231.0 million, up 2.21%.
  • Total Current Liabilities for Q4 2025 was $231.0 million at Arcus Biosciences, down from $235.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for RCUS hit a ceiling of $235.0 million in Q3 2025 and a floor of $130.4 million in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $188.0 million (2023), compared with a mean of $186.1 million.
  • Peak annual rise in Total Current Liabilities hit 528.71% in 2021, while the deepest fall reached 12.28% in 2021.
  • Arcus Biosciences' Total Current Liabilities stood at $166.0 million in 2021, then increased by 16.27% to $193.0 million in 2022, then dropped by 4.66% to $184.0 million in 2023, then rose by 22.83% to $226.0 million in 2024, then increased by 2.21% to $231.0 million in 2025.
  • The last three reported values for Total Current Liabilities were $231.0 million (Q4 2025), $235.0 million (Q3 2025), and $210.0 million (Q2 2025) per Business Quant data.